ahlam1399
06-26-2015, 10:50 AM
BRIEF-Swedish Orphan Biovitrum says EMA validates Alprolix marketing authorisation application
* The European Medicines Agency (EMA) has accepted the companies' Marketing Authorisation Application (MAA) of Alprolix (rFIXFc), a recombinant factor IX Fc fusion protein product candidate for the treatment of haemophilia B.http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4796bd3a/sc/28/mf.gif?resize=1%2C1
http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=55p5d9tVbiY:Zne_PQSU-2o:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=55p5d9tVbiY:Zne_PQSU-2o:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=55p5d9tVbiY:Zne_PQSU-2o:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=55p5d9tVbiY:Zne_PQSU-2o:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=55p5d9tVbiY:Zne_PQSU-2o:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/55p5d9tVbiY
* The European Medicines Agency (EMA) has accepted the companies' Marketing Authorisation Application (MAA) of Alprolix (rFIXFc), a recombinant factor IX Fc fusion protein product candidate for the treatment of haemophilia B.http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4796bd3a/sc/28/mf.gif?resize=1%2C1
http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=55p5d9tVbiY:Zne_PQSU-2o:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=55p5d9tVbiY:Zne_PQSU-2o:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=55p5d9tVbiY:Zne_PQSU-2o:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=55p5d9tVbiY:Zne_PQSU-2o:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=55p5d9tVbiY:Zne_PQSU-2o:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/55p5d9tVbiY